A

AtriCure
D

ATRC

35.610
USD
0.20
(0.56%)
مغلق
حجم التداول
9,457
الربح لكل سهم
-0
العائد الربحي
-
P/E
-46
حجم السوق
1,769,867,388
أصول ذات صلة
ABT
ABT
-1.470
(-1.12%)
130.290 USD
BDX
BDX
-0.860
(-0.44%)
195.060 USD
BSX
BSX
-0.110
(-0.11%)
103.070 USD
EW
EW
0.050
(0.06%)
78.300 USD
ISRG
ISRG
1.08
(0.23%)
481.16 USD
JNJ
JNJ
-0.405
(-0.23%)
176.245 USD
MDT
MDT
-0.165
(-0.18%)
92.835 USD
PFE
PFE
-0.100
(-0.40%)
25.055 USD
RMD
RMD
1.00
(0.35%)
286.09 USD
SYK
SYK
-0.15
(-0.04%)
381.66 USD
TMO
TMO
-1.42
(-0.29%)
487.77 USD
المزيد
الأخبار المقالات

العنوان: AtriCure

القطاع: Healthcare
الصناعة: Medical Instruments & Supplies
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct salesforce and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.